Abstract: A thermoplastic film which exhibits elastic-like behavior along at least one axis when stretched or elongated and then released. The thermoplastic film comprises a plurality of raised rib-like elements extending in a direction perpendicular to a main surface of the thermoplastic film. The thermoplastic film further includes a plurality of web areas positioned about the plurality of raised rib-like elements. The plurality of raised rib-like elements and plurality of web areas are arranged in a complex pattern. The complex pattern provides visual and tactile cues as the films are stretched or elongated. The complex pattern can cause the thermoplastic film to have a complex stretch profile.

Abstract: A method for treating waste water containing ammonia comprising the steps of: i) passing the waste water as a feed solution through a first RO membrane (24) to produce a first permeate stream (30) and a first reject stream (32), ii) adjusting the pH of the first reject stream (32) to >9, iii) passing the first reject stream (32) through a second RO membrane (26) to produce a second permeate stream (36) containing ammonia and a second reject stream (38), and iv) passing at least a portion of the second permeate stream (36) to a cooling tower (12) to evaporate at least a portion of the ammonia.

Abstract: A method for treating waste water containing ammonia comprising the steps of: i) passing the waste water as a feed solution through a first RO membrane (24) to produce a first permeate stream (30) and a first reject stream (32), ii) adjusting the pH of the first reject stream (32) to >9, iii) passing the first reject stream (32) through a second RO membrane (26) to produce a second permeate stream (36) containing ammonia and a second reject stream (38), and iv) passing at least a portion of the second permeate stream (36) to a cooling tower (12) to evaporate at least a portion of the ammonia.

Abstract: Disclosed are the ERK inhibitors of formula 1.0: and the pharmaceutically acceptable salts and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substituents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.

Abstract: Disclosed are the ERK inhibitors of formula 1.0: and the pharmaceutically acceptable salts and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.

Abstract: Disclosed are the ERK inhibitors of formula 1.0: and the pharmaceutically acceptable salts and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.

Abstract: Disclosed are novel tricyclic compounds of the formula: and the pharmaceutically acceptable salts thereof. Y is C or CH. When Y is C then Z is not present and the optional bond from Y to the C-11 carbon of the tricyclic nucleus is present. When Y is CH then Z is present and Z is H or —OH. The compounds are useful for inhibiting farnesyl protein transferase. Also disclosed are pharmaceutical compositions comprising the compounds of formula 1.0. Also disclosed are methods of treating cancer using the compounds of formula 1.0.

Abstract: The present invention provides compounds of formula I wherein X, Y, R1-R7 are as defined herein. Compositions containing these compounds, and methods for inhibiting HCV RNA-dependent RNA polymerase and treating hepatitis C and related disorders using these compounds and compositions are also provided.

Abstract: Disclosed are novel tricyclic compounds of the formula: and a pharmaceutically acceptable salts or solvates thereof. The compounds are useful for inhibiting farnesyl protein transferase. Also disclosed are pharmaceutical compositions comprising the compounds of formula (I). Also disclosed are uses of the compounds of formula (I) for the manufacture of a medicament for the treatment of cancer.